Cellectar Biosciences Inc (CLRB)

[Crusader]

WHere is the BOTTOM LINE of CLRB for MM patients:

Page 10 from the CLRB data presentation in my last post below.

It shows trial result numbers better than CAR-T trials and on-going CLR131 ORR as good and becoming better than MM drugs now being sold when they were at this stage of CLRB’s clinical trials- ON SEVERAL FORM OF CANCER, NOT JUST MM!

The FDA has approved many popular MM drugs such as Pomalyst which had an ORR of just 30% in its clinical trials. ( SEE PAGE 9 of presentation linked below) Now Pomalyst is selling at $17,000 for 21 4mg pills = one month dosing for use with Decadron once a week.

According to page 10 of the presentation ( https://seekingalpha.com/article/4316868-cellectar-biosciences-clrb-presents-biotech-showcase-2020-slideshow?dr=1&source=2800:read_now&utm_medium=email&utm_source=seeking_alpha ) CLR131 has already met and exceeded Pomalyst’s ORR IN CLINICAL TRIALS results (page 9) before Celegene was approved to market Pomalyst.

I BELIEVE CLRB WILL BE BOUGHT OUT (M&A) BY BIG PHARMA WITHIN ONE YEAR FOR REASONS REFLECTED IN LINK ABOVE OF CLRB’s PUBLIC PRESENTATION SCHEDULED FOR 2-19-20.

Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020
BY GlobeNewswire
— 8:00 AM ET 01/09/2020
FLORHAM PARK, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences ( CLRB
), Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it will host a Clinical Data Call on Wednesday, February 19, 2020 at 10:30 am Eastern Time.